Table 3 Summary of different organic nanomaterials used as drug delivery carrier for anticancer drugs
From: Current trends and challenges in cancer management and therapy using designer nanomaterials
Nanocarrier | Materials | Drug | Target | References |
|---|---|---|---|---|
Liposomes | Hyaluronic acid–ceramide and egg phosphatidylcholine | Doxorubicin | Human breast cancer (in vitro/in vivo) | [247] |
DSPE-PEG2000-Pen, DSPE-PEG2000-Tf | 5-Fluorouracil | Human glioblastoma (in vitro) | [248] | |
DPPC, MPPC | Tamoxifen, imatinib | Human breast cancer (in vitro) | [97] | |
DPPC, cholesterol, DSPE-PEG-FA | Celastrol and irinotecan | Human Breast cancer (in vitro/in vivo) | [236] | |
DSPE-PEG2000-NHS, pHCT74 peptide | Doxorubicin | Human prostate cancer (in vitro/in vivo) | [249] | |
CHEMS, DOPE, DSPE-PEG2000 | Tariquidar and doxorubicin | Human ovarian cancer (in vitro) | [241] | |
Egg phosphatidylcholine, DOPE, CHEMS, DSPE-PEG2000 | Resveratrol | Human glioblastoma (in vitro) | [237] | |
PC, DSPE-PEG2000 | Doxorubicin and celecoxib | Human skin cancer (in vitro) | [250] | |
Polymeric nanoparticles | PLGA [poly(lactic-co-glycolic acid)], PVA [poly(vinyl alcohol)] | Abiraterone acetate and docetaxel | Human prostate cancer (in vitro) | [251] |
MPEG-PVA [poly(vinyl alcohol)] | Verapamil and doxorubicin | Human ovarian cancer (in vitro) | [252] | |
PLGA [poly(lactic-co-glycolic acid)], PVA [poly(vinyl alcohol)] | Resveratrol | Human prostate cancer (in vitro) | [253] | |
PLA | Calcitriol | Human breast cancer (in vitro) | [254] | |
TPGS-b-PCL, Pluronic P123 | Sorafenib | Human liver carcinoma (in vitro/in vivo) | [255] | |
PLGA [poly(lactic-co-glycolic acid)], PEG, chitosan | Curcumin | Human pancreatic cancer (in vitro) | [256] | |
PLGA [poly(lactic-co-glycolic acid)], DSPE-PEG | Docetaxel | Human tongue carcinoma (in vitro) | [257] | |
Dendrimers | PAMAM, octa-arginine, PEG | Paclitaxel | Human cervical carcinoma (in vitro) | [258] |
PAMAM, N-acetylgalactosamine ligand, PEG | Doxorubicin | Hepatocellular carcinoma (in vivo) | [259] | |
PAMAM, lactobionic acid | Sorafenib | Human liver cancer (in vitro) | [260] | |
PAMAM, folic acid | Baicalin | Human cervical cancer (in vitro) | [261] | |
PAMAM, PEG, AS1411-aptamer | Camptothecin | Human colon adenocarcinoma (in vitro/in vivo) | [262] | |
PAMAM, OEG | Methotrexate | Human breast cancer (in vitro/in vivo) | [263] | |
h-PAMAM, PEG-SC | Doxorubicin | Human gastric cancer (in vitro/in vivo) | [264] |